| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US7635773 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US8410077 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9200088 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9493582 | LUPIN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
Sesquient is owned by Lupin.
Sesquient contains Fosphenytoin Sodium.
Sesquient has a total of 5 drug patents out of which 0 drug patents have expired.
Sesquient was authorised for market use on 05 November, 2020.
Sesquient is available in solution;intravenous dosage forms.
The generics of Sesquient are possible to be released after 27 February, 2033.
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
SESQUIENT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic